The Australian government will invest $1 billion over 12 years to ensure its sovereign capability to produce and access vaccines in future pandemics.
This comes as Seqirus, a subsidiary of CSL, announced that it would build a new $800 million biotech manufacturing facility in Australia to supply influenza vaccines to Australia and the world.
